First Drug for BRCA Breast Cancer: Olaparib

Olaparib has achieved two firsts in breast cancer: it’s the first PARP inhibitor and the first drug for patients carrying the BRCA mutation.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply